CHI’s Inaugural Pathway Analysis
Venue: San Francisco
|Event Date/Time: Apr 20, 2005||End Date/Time: Apr 22, 2005|
Expression profiling is driving the pharmaceutical R&D process. It is being used downstream of target identification, as a biological readout for target modulation. Targets first identified through genomics then need to go through validation testing, to see if a phenotypic change occurs when a target is disregulated. These targets or pathways can be modified by using either RNAi, or the use of a chemical ligand that interacts with a target. The results are compared in order to understand a compound’s activity for on- and off- target effects. Pathway elucidation is critical to this process, in order to both identify the biochemical components in a pathway associated with disease, and the affect of a chemical entity on this pathway. This synergistic approach will help to identify ways to validate and prioritize targets, and enable us to understand the molecular mechanism of therapeutics.